• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (OP:RVVTF)

0.0380 +0.0049 (+14.80%)
Streaming Delayed Price Updated: 3:53 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,952,803
Open 0.0321
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0331
Today's Range 0.0310 - 0.0425
52wk Range 0.0052 - 0.0425
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
March 11, 2026
Via ACCESS Newswire
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
December 15, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire

Performance

YTD
+313.0%
+313.0%
1 Month
+406.7%
+406.7%
3 Month
+276.2%
+276.2%
6 Month
+216.7%
+216.7%
1 Year
+493.7%
+493.7%

More News

Read More
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
November 21, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
September 19, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Extension of Proposed Private Placement
September 05, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
August 11, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
July 30, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
July 08, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
June 26, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Advances with Next-Generation Bucillamine Development
June 04, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
May 12, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Proposed Shares for Debt Transaction
April 21, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
April 10, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
April 01, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Results of Annual Shareholder Meeting
March 19, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
March 03, 2025
Via Newsfile
News headline image
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
March 03, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
February 03, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
January 08, 2025
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
November 12, 2024
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
October 31, 2024
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
September 18, 2024
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
August 28, 2024
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗
July 31, 2024
Via Benzinga
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
July 02, 2024
From Revive Therapeutics Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Revive Therapeutics Ltd publicly traded?
Yes, Revive Therapeutics Ltd is publicly traded.
What exchange does Revive Therapeutics Ltd trade on?
Revive Therapeutics Ltd trades on the OTC Traded
What is the ticker symbol for Revive Therapeutics Ltd?
The ticker symbol for Revive Therapeutics Ltd is RVVTF on the OTC Traded
What is the current price of Revive Therapeutics Ltd?
The current price of Revive Therapeutics Ltd is 0.0380
When was Revive Therapeutics Ltd last traded?
The last trade of Revive Therapeutics Ltd was at 03/13/26 03:53 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap